Altered significance of D'Amico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort.

@article{Bolton2015AlteredSO,
  title={Altered significance of D'Amico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort.},
  author={Damien M Bolton and Yuan Cheng and Amber J. Willems-Jones and Jason Li and Eveline Niedermeyr and Gillian Mitchell and David Clouston and Nathan L Lawrentschuk and Ania Sliwinski and Stephen B Fox and Heather J Thorne},
  journal={BJU international},
  year={2015},
  volume={116 2},
  pages={
          207-12
        }
}
OBJECTIVE To ascertain whether D'Amico risk classification is an accurate discriminator of prostate cancer mortality risk in BRCA2 pathogenic mutation carriers and non-carriers from a familial breast cancer cohort. PATIENTS AND METHODS From family cancer pedigrees of patients evaluated through a familial breast cancer cohort all related men with a diagnosis of prostate cancer were identified. Genotyping of each patient or of the dominant familial BRCA2 mutation was undertaken in each instance… CONTINUE READING
2
Twitter Mentions

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2010

The 2010 NCCN clinical practice guidelines in oncology on prostate cancer.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2010

Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004